IN8bio (NASDAQ:INAB) Posts Earnings Results

IN8bio (NASDAQ:INAB) posted its earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.10, FiscalAI reports.

IN8bio Stock Performance

NASDAQ INAB traded up $0.10 on Friday, hitting $0.93. 33,376 shares of the stock were exchanged, compared to its average volume of 39,109. The stock has a fifty day moving average price of $1.13 and a two-hundred day moving average price of $1.42. The firm has a market capitalization of $9.14 million, a P/E ratio of -0.92 and a beta of 0.27. IN8bio has a 52-week low of $0.80 and a 52-week high of $2.73.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.